Growth Metrics

Regenxbio (RGNX) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to -$62.0 million.

  • Regenxbio's Income from Continuing Operations fell 392.14% to -$62.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$178.1 million, marking a year-over-year increase of 2551.16%. This contributed to the annual value of -$227.1 million for FY2024, which is 1381.13% up from last year.
  • Latest data reveals that Regenxbio reported Income from Continuing Operations of -$62.0 million as of Q3 2025, which was down 392.14% from -$70.9 million recorded in Q2 2025.
  • Regenxbio's Income from Continuing Operations' 5-year high stood at $294.1 million during Q4 2021, with a 5-year trough of -$76.7 million in Q1 2022.
  • Its 5-year average for Income from Continuing Operations is -$40.5 million, with a median of -$61.9 million in 2023.
  • Examining YoY changes over the last 5 years, Regenxbio's Income from Continuing Operations showed a top increase of 73597.02% in 2021 and a maximum decrease of 76437.27% in 2021.
  • Over the past 5 years, Regenxbio's Income from Continuing Operations (Quarter) stood at $294.1 million in 2021, then crashed by 120.38% to -$59.9 million in 2022, then fell by 5.18% to -$63.0 million in 2023, then rose by 18.67% to -$51.3 million in 2024, then decreased by 20.85% to -$62.0 million in 2025.
  • Its last three reported values are -$62.0 million in Q3 2025, -$70.9 million for Q2 2025, and $6.1 million during Q1 2025.